Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 17, 2020 (Event Date: July 20, 2020)
Context: The Company reported the completion of an underwritten public offering of common stock on July 20, 2020, following the full exercise of an over-allotment option by underwriters on July 17, 2020.
Key Financial Metrics
Capital Raised: The Company issued and sold an aggregate of 2,500,000 shares of common stock at a public offering price of $10.00 per share.
Net Proceeds: Approximately $23.1 million, after deducting underwriting discounts, commissions, and estimated offering expenses.
Operating Metrics: The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period.
Material Changes
Capital Structure: The Company increased its outstanding common stock by 2,500,000 shares through the Offering.
Liquidity: The transaction significantly increased the Company's cash position with net proceeds of approximately $23.1 million.
Outlook, Management Commentary, and Risks
Use of Proceeds: Management intends to use the net proceeds for general corporate purposes, specifically to support research and development, including clinical trials.
Regulatory Status: The offering was conducted pursuant to a shelf registration statement on Form S-3 (File No. 333-237368) effective as of April 2, 2020.
Risks: The filing does not explicitly detail new risks or contingencies beyond the standard nature of clinical trial development implied by the use of proceeds.
Investor Verification Checklist
- Verify the final closing date of the offering (July 20, 2020) and the full exercise of the over-allotment option.
- Confirm the exact net proceeds received ($23.1 million) against the gross proceeds ($25.0 million) to understand underwriting costs.
- Review the attached Press Release (Exhibit 99.1) for detailed allocation of funds to specific clinical trials.
- Check subsequent filings for updates on the utilization of the raised capital and progress of R&D programs.